Price$124.18+2.01 (+1.64%)
01:30 PM07:45 PM
News · 26 weeks66-35%
2025-12-282026-06-21
Mix4190d
- Insider12(29%)
- SEC Filings10(24%)
- Other10(24%)
- Analyst4(10%)
- Leadership3(7%)
- Dividends2(5%)
Latest news
25 items- PRTeleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium ScaffoldEnrollment completed ahead of schedule in BIOMAG™-II Positive four-year BIOMAG™-I results recently reported Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (NCT07258290), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). Dr. Itsik Ben-Dor, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of Freesolve™ RMS to date. Cha
- SECTeleflex Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - TELEFLEX INC (0000096943) (Filer)
- INSIDERDirector Randle Stuart A covered exercise/tax liability with 4,054 shares and was granted 5,658 shares, increasing direct ownership by 8% to 21,187 units (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- INSIDERPresident and CEO Weidman Jason R. was granted 53,983 shares (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- INSIDERSEC Form 3 filed by new insider Weidman Jason R.3 - TELEFLEX INC (0000096943) (Issuer)
- SECTeleflex Incorporated filed SEC Form 8-K: Leadership Update8-K - TELEFLEX INC (0000096943) (Filer)
- PRFour‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)Persistently Low Target Lesion Failure and No New Cardiac-Related Event Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the four‑year follow‑up data from the First-in-Human BIOMAG™-I Clinical Study (NCT04157153)* presented at the EuroPCR conference in Paris, France by Prof. Jan Torzewski (Klinikverbund Allgäu, Germany). Conducted exclusively across European centers and enrolling 116 patients, the study continues to demonstrate a favorable long‑term safety profile1, with no new cardiac‑related1 events observed between two and four years follow‑up period, establishing the third-generation Freesolve™ Resorbable Magnesium Scaffold (RMS) a
- ANALYSTTeleflex upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Teleflex from Neutral to Overweight and set a new price target of $160.00
- PRTeleflex Incorporated Announces Pricing of $500 Million Senior Notes OfferingTeleflex Incorporated (NYSE:TFX) ("Teleflex") announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the "Notes") at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness. Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the "2027 Notes").
- SECTeleflex Incorporated filed SEC Form 8-K: Other Events, Regulation FD Disclosure8-K - TELEFLEX INC (0000096943) (Filer)
- PRTeleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032Teleflex Incorporated (NYSE:TFX) ("Teleflex") announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the "Notes"), subject to market and other conditions. The interest rate and other terms of the Notes will be determined at pricing. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness. Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the "2027 Notes"). The offering of t
- SECSEC Form SD filed by Teleflex IncorporatedSD - TELEFLEX INC (0000096943) (Filer)
- SECTeleflex Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - TELEFLEX INC (0000096943) (Filer)
- PRTeleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal SpacerFirst Head-to-Head Randomized Control Study (RCT) Reinforces Early Patient Experience Benefits and 12-month Durability of the UroLift™ System versus Rezūm™1 Three-Year Data Demonstrate Sustained Reduction in Gastrointestinal Toxicity with Barrigel™ Rectal Spacer2 Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innova
- SECTeleflex Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - TELEFLEX INC (0000096943) (Filer)
- INSIDERDirector Ryu Jaewon was granted 1,090 shares, increasing direct ownership by 29% to 4,817 units (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- INSIDERDirector Krakauer Andrew A was granted 1,090 shares, increasing direct ownership by 15% to 8,309 units (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- INSIDERDirector Haggerty Gretchen R was granted 1,090 shares, increasing direct ownership by 17% to 7,395 units (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- INSIDERDirector Duncan Candace H was granted 1,090 shares, increasing direct ownership by 18% to 7,039 units (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- INSIDERDirector Tokich Michael J was granted 1,090 shares (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- INSIDERDirector Patil Neena M was granted 1,090 shares, increasing direct ownership by 42% to 3,716 units (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tokich Michael J3 - TELEFLEX INC (0000096943) (Issuer)
- PRTeleflex Announces Quarterly DividendTeleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believ
- INSIDERInterim President and CEO Randle Stuart A covered exercise/tax liability with 289 shares, decreasing direct ownership by 1% to 19,583 units (SEC Form 4)4 - TELEFLEX INC (0000096943) (Issuer)
- ANALYSTTeleflex upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded Teleflex from Sector Perform to Outperform and set a new price target of $155.00
TFX FAQ
7 questionsWhat does Teleflex Incorporated do?
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary...Where does TFX stock trade?
Teleflex Incorporated (TFX) is listed on NYSE.What sector and industry is TFX in?
Teleflex Incorporated operates in the Health Care sector, Medical/Dental Instruments industry.Does TFX pay a dividend?
TFX's most recent ex-dividend date was 2026-05-22 with a cash dividend of $0.34 per share. No future ex-date is on file yet.What are analysts saying about TFX?
Teleflex Incorporated has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight on 2026-06-08.What companies are similar to TFX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare TFX side-by-side with any of them on Quantisnow.How can I track TFX on Quantisnow?
Quantisnow aggregates Teleflex Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TFX to receive live email and push alerts on every new disclosure.